{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:25:16Z","timestamp":1792182316280,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001794","name":"The University of Queensland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40263-025-01177-5","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T12:45:26Z","timestamp":1742733926000},"page":"597-607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clozapine-Related Tachycardia: An Analysis of Incidence"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6455-9741","authenticated-orcid":false,"given":"Susanna","family":"Every-Palmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6268-547X","authenticated-orcid":false,"given":"Korinne","family":"Northwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0141-5740","authenticated-orcid":false,"given":"James","family":"Tsakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3837-8140","authenticated-orcid":false,"given":"Matthew K.","family":"Burrage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2072-9216","authenticated-orcid":false,"given":"Dan","family":"Siskind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,23]]},"reference":[{"issue":"5","key":"1177_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","volume":"209","author":"D Siskind","year":"2016","unstructured":"Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5):385\u201392.","journal-title":"Br J Psychiatry"},{"issue":"3","key":"1177_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1192\/bjp.2021.61","volume":"220","author":"D Siskind","year":"2022","unstructured":"Siskind D, Orr S, Sinha S, Yu O, Brijball B, Warren N, et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry. 2022;220(3):115\u201320.","journal-title":"Br J Psychiatry"},{"issue":"7","key":"1177_CR3","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/14740338.2024.2362796","volume":"23","author":"T Tanzer","year":"2024","unstructured":"Tanzer T, Pham B, Warren N, Barras M, Kisely S, Siskind D. Overcoming clozapine\u2019s adverse events: a narrative review of systematic reviews and meta-analyses. Expert Opin Drug Saf. 2024;23(7):811\u201331.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"1177_CR4","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/j.hrthm.2015.03.029","volume":"12","author":"RS Sheldon","year":"2015","unstructured":"Sheldon RS, Grubb BP II, Olshansky B, Shen W-K, Calkins H, Brignole M, et al. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12(6):e41\u201363.","journal-title":"Heart Rhythm"},{"issue":"6","key":"1177_CR5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.4088\/JCP.v61n0609","volume":"61","author":"UG Kang","year":"2000","unstructured":"Kang UG, Kwon JS, Ahn YM, Chung SJ, Ha JH, Koo YJ, et al. Electrocardiographic abnormalities in patients treated with clozapine. J Clin Psychiatry. 2000;61(6):441\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1177_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/YIC.0000000000000169","volume":"32","author":"BM Nilsson","year":"2017","unstructured":"Nilsson BM, Edstr\u00f6m O, Lindstr\u00f6m L, Wernegren P, Bod\u00e9n R. Tachycardia in patients treated with clozapine versus antipsychotic long-acting injections. Int Clin Psychopharmacol. 2017;32(4):219\u201324.","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"1177_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2174\/157488631002150515120209","volume":"10","author":"N Hyde","year":"2015","unstructured":"Hyde N, Dodd S, Venugopal K, Purdie C, Berk M, O\u2019Neil A. Prevalence of cardiovascular and metabolic events in patients prescribed clozapine: a retrospective observational, clinical cohort study. Curr Drug Saf. 2015;10(2):125\u201331.","journal-title":"Curr Drug Saf"},{"issue":"6","key":"1177_CR8","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1097\/JCP.0b013e318234ee66","volume":"31","author":"C Rostagno","year":"2011","unstructured":"Rostagno C, Domenichetti S, Pastorelli F, Gensini GF. Usefulness of NT-pro-BNP and echocardiography in the diagnosis of subclinical clozapine-related cardiotoxicity. J Clin Psychopharmacol. 2011;31(6):712\u20136.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"1177_CR9","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1046\/j.0306-5251.2001.01448.x","volume":"52","author":"J Pretorius","year":"2001","unstructured":"Pretorius J, Phillips M, Langley R, Szabadi E, Bradshaw C. Comparison of clozapine and haloperidol on some autonomic and psychomotor functions, and on serum prolactin concentration, in healthy subjects. Br J Clin Pharmacol. 2001;52(3):322\u20136.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1177_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1177\/10398562231224156","volume":"32","author":"D Brennan","year":"2024","unstructured":"Brennan D, Lal S, Hugo F, Waters F, Shymko G. Clozapine-related tachycardia: a conundrum to identify and treat. Australas Psychiatry. 2024;32(1):84\u20138.","journal-title":"Australas Psychiatry"},{"issue":"6","key":"1177_CR11","doi-asserted-by":"publisher","first-page":"336","DOI":"10.9740\/mhc.2022.12.336","volume":"12","author":"RT Santos","year":"2022","unstructured":"Santos RT, Mullen S, Crouse EL, Adams KS. Comparison of clozapine doses and tolerability in patients with and without concurrent valproic acid. Ment Health Clin. 2022;12(6):336\u201341.","journal-title":"Ment Health Clin."},{"issue":"3","key":"1177_CR12","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/oxfordjournals.schbul.a033333","volume":"24","author":"CR Young","year":"1998","unstructured":"Young CR, Bowers MB Jr, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull. 1998;24(3):381\u201390.","journal-title":"Schizophr Bull"},{"issue":"4","key":"1177_CR13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0735-1097(96)00592-X","volume":"29","author":"JS Shinbane","year":"1997","unstructured":"Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29(4):709\u201315.","journal-title":"J Am Coll Cardiol"},{"issue":"9193","key":"1177_CR14","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1016\/S0140-6736(99)10385-4","volume":"354","author":"JG Kilian","year":"1999","unstructured":"Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 1999;354(9193):1841\u20135.","journal-title":"Lancet"},{"issue":"3","key":"1177_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1192\/pb.38.3.140a","volume":"38","author":"WR Jones","year":"2014","unstructured":"Jones WR, Narayana U, Howarth S, Nazar QN. Psychiatr Bull. 2014;38(3):140.","journal-title":"Psychiatr Bull"},{"issue":"6","key":"1177_CR16","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.numecd.2017.04.004","volume":"27","author":"D Aune","year":"2017","unstructured":"Aune D, Sen A, \u00f3\u2019Hartaigh B, Janszky I, Romundstad PR, Tonstad S, et al. Resting heart rate and the risk of cardiovascular disease, total cancer, and all-cause mortality\u2013a systematic review and dose\u2013response meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis. 2017;27(6):504\u201317.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"9","key":"1177_CR17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.121.007960","volume":"15","author":"KA Mayuga","year":"2022","unstructured":"Mayuga KA, Fedorowski A, Ricci F, Gopinathannair R, Dukes JW, Gibbons C, et al. Sinus tachycardia: a multidisciplinary expert focused review. Circ Arrhythm Electrophysiol. 2022;15(9): e007960.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"1177_CR18","unstructured":"Australian Commission on Safety and Quality in Health Care. National Inpatient Medication Chart (NIMC) - Clozapine titration guide. 2023. Available at: https:\/\/www.safetyandquality.gov.au\/our-work\/medication-safety\/medication-charts\/national-standard-medication-charts\/clozapine-titration-chart. Accessed January 2025."},{"key":"1177_CR19","unstructured":"R Core Team. R: A Language and environment for statistical computing. R version 4.3.2 (2023-10-31) ed. Vienna, Austria: R Foundation for Statistical Computing; 2023."},{"key":"1177_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.schres.2018.03.017","volume":"199","author":"BM Nilsson","year":"2018","unstructured":"Nilsson BM, Lindstr\u00f6m L, Mohsen I, Holml\u00f6v K, Bod\u00e9n R. Persistent tachycardia in clozapine treated patients: a 24-hour ambulatory electrocardiogram study. Schizophr Res. 2018;199:403\u20136.","journal-title":"Schizophr Res"},{"issue":"1\u20133","key":"1177_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.schres.2016.05.002","volume":"174","author":"SE Legge","year":"2016","unstructured":"Legge SE, Hamshere M, Hayes RD, Downs J, O\u2019Donovan MC, Owen MJ, et al. Reasons for discontinuing clozapine: a cohort study of patients commencing treatment. Schizophr Res. 2016;174(1\u20133):113\u20139.","journal-title":"Schizophr Res"},{"key":"1177_CR22","first-page":"122","volume":"55","author":"A Breier","year":"1994","unstructured":"Breier A. Clozapine and noradrenergic function: support for a novel hypothesis for superior efficacy. J Clin Psychiatry. 1994;55:122\u20135.","journal-title":"J Clin Psychiatry"},{"key":"1177_CR23","doi-asserted-by":"publisher","unstructured":"Lally J, Docherty MJ, MacCabe JH. Pharmacological interventions for clozapine-induced sinus tachycardia. Cochrane Database Syst Rev. 2016;(6). https:\/\/doi.org\/10.1002\/14651858.CD011566.pub2","DOI":"10.1002\/14651858.CD011566.pub2"},{"key":"1177_CR24","first-page":"6352175","volume":"1","author":"S Adeyemo","year":"2020","unstructured":"Adeyemo S, Jegede O, Rabel P, Ahmed S, Tumenta T, Oladeji O, et al. Persistent tachycardia in a patient on clozapine. Case Rep Psychiatry. 2020;1:6352175.","journal-title":"Case Rep Psychiatry."},{"issue":"6","key":"1177_CR25","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3109\/00048674.2011.572852","volume":"45","author":"KJ Ronaldson","year":"2011","unstructured":"Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry. 2011;45(6):458\u201365.","journal-title":"Aust N Z J Psychiatry"},{"issue":"6","key":"1177_CR26","doi-asserted-by":"publisher","first-page":"20799","DOI":"10.4088\/JCP.12r08064","volume":"74","author":"J Nielsen","year":"2013","unstructured":"Nielsen J, Correll CU, Manu P, Kane JM. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry. 2013;74(6):20799.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"1177_CR27","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/WNF.0b013e3181a620b2","volume":"32","author":"R Stryjer","year":"2009","unstructured":"Stryjer R, Timinsky I, Reznik I, Weizman A, Spivak B. \u03b2-adrenergic antagonists for the treatment of clozapine-induced sinus tachycardia: a retrospective study. Clin Neuropharmacol. 2009;32(5):290\u20132.","journal-title":"Clin Neuropharmacol"},{"key":"1177_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3389\/fnins.2018.00203","volume":"12","author":"JW Yuen","year":"2018","unstructured":"Yuen JW, Kim DD, Procyshyn RM, White RF, Honer WG, Barr AM. Clozapine-induced cardiovascular side effects and autonomic dysfunction: a systematic review. Front Neurosci. 2018;12:203.","journal-title":"Front Neurosci"},{"issue":"4","key":"1177_CR29","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/schbul\/sbad030","volume":"49","author":"E Wagner","year":"2023","unstructured":"Wagner E, Siskind D, Falkai P, Howes O, Correll C, Lee J, et al. Clozapine optimization: a Delphi consensus guideline from the treatment response and resistance in psychosis working group. Schizophr Bull. 2023;49(4):962\u201372.","journal-title":"Schizophr Bull"},{"issue":"1","key":"1177_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/bmb\/ldaa024","volume":"135","author":"R Flanagan","year":"2020","unstructured":"Flanagan R, Lally J, Gee S, Lyon R, Every-Palmer S. Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals. Br Med Bull. 2020;135(1):73\u201389.","journal-title":"Br Med Bull"},{"issue":"3","key":"1177_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/2045125313512325","volume":"4","author":"J Lally","year":"2014","unstructured":"Lally J, Brook J, Dixon T, Gaughran F, Shergill S, Melikian N, et al. Ivabradine, a novel treatment for clozapine-induced sinus tachycardia: a case series. Ther Adv Psychopharmacol. 2014;4(3):117\u201322.","journal-title":"Ther Adv Psychopharmacol."},{"issue":"2","key":"1177_CR32","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/schbul\/sbr148","volume":"39","author":"AJ Mitchell","year":"2013","unstructured":"Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2014a systematic review and meta-analysis. Schizophr Bull. 2013;39(2):306\u201318.","journal-title":"Schizophr Bull"},{"key":"1177_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.609240","volume":"12","author":"JW Yuen","year":"2021","unstructured":"Yuen JW, Kim DD, Procyshyn RM, Panenka WJ, Honer WG, Barr AM. A focused review of the metabolic side-effects of clozapine. Front Endocrinol (Lausanne). 2021;12: 609240.","journal-title":"Front Endocrinol (Lausanne)."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01177-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01177-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01177-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T12:30:46Z","timestamp":1746621046000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01177-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,23]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1177"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01177-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,23]]},"assertion":[{"value":"9 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The dataset is available from the corresponding author on request and with appropriate ethics approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Metro South Human Research Ethics Committee - HREC\/2020\/QMS\/60964.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"This was a study of a retrospective de-identified data extract, with a waiver of\u00a0consent\u00a0as part of the ethics approval.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions. The authors did not receive support from any organization for the submitted work. The open access fee is covered by the authors\u2019 university publishing agreements through the Council of Australasian University Librarians membership.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare they have no financial conflicts of interests. Susanna Every-Palmer is an Editorial Board member of CNS Drugs. Professor Every-Palmer was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interests"}},{"value":"Conceptualization and design of the study\u2014D.S.; methodology\u2014D.S., S.E.P. and K.N.; data extraction\u2014J.T.; formal analysis and investigation\u2014K.N., S.E.P. and D.S.; writing\u2014original draft preparation\u2014S.E.P. and K.N.; writing\u2014review and editing\u2014S.E.P., K.N., D.S., J.T. and M.K.B. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}